title: Recanalization after thrombolysis in stroke patients: predictors and prognostic implications.
abstract: OBJECTIVE
  To estimate rates, predictors, and prognostic importance of recanalization in an unselected series of patients with stroke treated with IV thrombolysis.
  
  
  METHODS
  We performed a CT angiography or transcranial Doppler (TCD) follow-up examination 24 hours after IV thrombolysis in 64 patients with documented occlusion of the intracranial internal carotid or middle cerebral artery (MCA). Complete recanalization was defined by a rating of 3 on the Thrombolysis in Myocardial Infarction or 4/5 on the Thrombolysis in Brain Ischemia grading scales. Information about risk factors, clinical features, and outcome was prospectively collected by standardized procedures.
  
  
  RESULTS
  Complete recanalization was achieved in 36 of the 64 patients (56.3%). There was a nonsignificant trend of recanalization rates to decline with a more proximal site of occlusion: 68.4% (M2 segment of MCA), 53.1% (M1 segment), and 46.2% (carotid T) (p for trend = 0.28). Frequencies of vessel reopening were markedly reduced in subjects with diabetes (9.1% vs 66.0% in nondiabetics, p < 0.001) and less so in subjects with additional extracranial carotid occlusion (p = 0.03). Finally, complete recanalization predicted a favorable stroke outcome at day 90 independently of the information provided by age, NIH Stroke Scale, and onset-to-needle time.
  
  
  CONCLUSIONS
  We found a high rate of vessel recanalization after IV thrombolysis occlusion. However, recanalization was infrequent in patients with diabetes and extracranial carotid occlusion. Information on recanalization was a powerful, early predictor for clinical outcome.
authors.affiliation: Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Zangerle
authors.forename: S
authors.initials: S
authors.lastname: Kiechl
authors.forename: M
authors.initials: M
authors.lastname: Spiegel
authors.forename: M
authors.initials: M
authors.lastname: Furtner
authors.forename: M
authors.initials: M
authors.lastname: Knoflach
authors.forename: P
authors.initials: P
authors.lastname: Werner
authors.forename: A
authors.initials: A
authors.lastname: Mair
authors.forename: G
authors.initials: G
authors.lastname: Wille
authors.forename: C
authors.initials: C
authors.lastname: Schmidauer
authors.forename: K
authors.initials: K
authors.lastname: Gautsch
authors.forename: T
authors.initials: T
authors.lastname: Gotwald
authors.forename: S
authors.initials: S
authors.lastname: Felber
authors.forename: W
authors.initials: W
authors.lastname: Poewe
authors.forename: J
authors.initials: J
authors.lastname: Willeit
mesh_terms: D000368:Aged; D002545:Brain Ischemia / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D020521:Stroke / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D010959:Tissue Plasminogen Activator